1. Home
  2. BOT vs CTMX Comparison

BOT vs CTMX Comparison

Compare BOT & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RoboStrategy Inc. Common Stock

BOT

RoboStrategy Inc. Common Stock

N/A

Current Price

$21.57

Market Cap

688.4M

Sector

N/A

ML Signal

N/A

Logo CytomX Therapeutics Inc.

CTMX

CytomX Therapeutics Inc.

N/A

Current Price

$2.21

Market Cap

716.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BOT
CTMX
Founded
N/A
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
688.4M
716.9M
IPO Year
2025
2015

Fundamental Metrics

Financial Performance
Metric
BOT
CTMX
Price
$21.57
$2.21
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
★ $12.25
AVG Volume (30 Days)
368.5K
★ 4.0M
Earning Date
N/A
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
★ $76,201,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$1.24
P/E Ratio
★ N/A
$22.58
Revenue Growth
★ N/A
N/A
52 Week Low
$20.12
$2.14
52 Week High
$43.72
$8.21

Technical Indicators

Market Signals
Indicator
BOT
CTMX
Relative Strength Index (RSI) 41.35 41.23
Support Level $20.41 N/A
Resistance Level $30.93 $2.61
Average True Range (ATR) 2.08 0.17
MACD -0.09 0.01
Stochastic Oscillator 31.38 16.00

Price Performance

Historical Comparison
BOT
CTMX

About BOT RoboStrategy Inc. Common Stock

RoboStrategy Inc is a closed-end, non-diversified management investment company. The Fund's investment objective is to seek long-term capital appreciation, principally through capital gains on equity and equity-linked investments in robotics and embodied AI companies. The Fund focuses on private, venture-capital-backed companies with growth potential, many of which are not yet publicly listed or widely accessible to individual investors.

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Share on Social Networks: